These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 19091655)

  • 1. [Everolimus (RAD001) and solid tumours: a 2008 summary].
    Lévy A; Sauvin LA; Massard C; Soria JC
    Bull Cancer; 2008 Dec; 95(12):1205-11. PubMed ID: 19091655
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The potential role of mTOR inhibitors in non-small cell lung cancer.
    Gridelli C; Maione P; Rossi A
    Oncologist; 2008 Feb; 13(2):139-47. PubMed ID: 18305058
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mammalian target of rapamycin is a promising target for novel therapeutic strategy against cancer.
    Bjelogrlić SK; Srdić T; Radulović S
    J BUON; 2006; 11(3):267-76. PubMed ID: 17309148
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I/II study of the mammalian target of rapamycin inhibitor everolimus (RAD001) in patients with relapsed or refractory hematologic malignancies.
    Yee KW; Zeng Z; Konopleva M; Verstovsek S; Ravandi F; Ferrajoli A; Thomas D; Wierda W; Apostolidou E; Albitar M; O'Brien S; Andreeff M; Giles FJ
    Clin Cancer Res; 2006 Sep; 12(17):5165-73. PubMed ID: 16951235
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase 2 study with a daily regimen of the oral mTOR inhibitor RAD001 (everolimus) in patients with metastatic clear cell renal cell cancer.
    Amato RJ; Jac J; Giessinger S; Saxena S; Willis JP
    Cancer; 2009 Jun; 115(11):2438-46. PubMed ID: 19306412
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mechanisms of mammalian target of rapamycin inhibition in sarcoma: present and future.
    MacKenzie AR; von Mehren M
    Expert Rev Anticancer Ther; 2007 Aug; 7(8):1145-54. PubMed ID: 18028023
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antiangiogenic therapy with mammalian target of rapamycin inhibitor RAD001 (Everolimus) increases radiosensitivity in solid cancer.
    Manegold PC; Paringer C; Kulka U; Krimmel K; Eichhorn ME; Wilkowski R; Jauch KW; Guba M; Bruns CJ
    Clin Cancer Res; 2008 Feb; 14(3):892-900. PubMed ID: 18245553
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Drug evaluation: AP-23573--an mTOR inhibitor for the treatment of cancer.
    Elit L
    IDrugs; 2006 Sep; 9(9):636-44. PubMed ID: 16952072
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I pharmacokinetic and pharmacodynamic study of the oral mammalian target of rapamycin inhibitor everolimus in patients with advanced solid tumors.
    O'Donnell A; Faivre S; Burris HA; Rea D; Papadimitrakopoulou V; Shand N; Lane HA; Hazell K; Zoellner U; Kovarik JM; Brock C; Jones S; Raymond E; Judson I
    J Clin Oncol; 2008 Apr; 26(10):1588-95. PubMed ID: 18332470
    [TBL] [Abstract][Full Text] [Related]  

  • 10. mTOR inhibitor RAD001 (everolimus) has antiangiogenic/vascular properties distinct from a VEGFR tyrosine kinase inhibitor.
    Lane HA; Wood JM; McSheehy PM; Allegrini PR; Boulay A; Brueggen J; Littlewood-Evans A; Maira SM; Martiny-Baron G; Schnell CR; Sini P; O'Reilly T
    Clin Cancer Res; 2009 Mar; 15(5):1612-22. PubMed ID: 19223496
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Topics in mTOR pathway and its inhibitors].
    Dreyer C; Sablin MP; Faivre S; Raymond E
    Bull Cancer; 2009 Jan; 96(1):87-94. PubMed ID: 19211363
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mammalian target of rapamycin inhibitors rapamycin and RAD001 (everolimus) induce anti-proliferative effects in GH-secreting pituitary tumor cells in vitro.
    Gorshtein A; Rubinfeld H; Kendler E; Theodoropoulou M; Cerovac V; Stalla GK; Cohen ZR; Hadani M; Shimon I
    Endocr Relat Cancer; 2009 Sep; 16(3):1017-27. PubMed ID: 19509067
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [mTOR signal pathway and its inhibitors in antitumor therapy: a review].
    Huang JJ; Lin TY
    Ai Zheng; 2007 Dec; 26(12):1397-403. PubMed ID: 18076811
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase I study of everolimus in pediatric patients with refractory solid tumors.
    Fouladi M; Laningham F; Wu J; O'Shaughnessy MA; Molina K; Broniscer A; Spunt SL; Luckett I; Stewart CF; Houghton PJ; Gilbertson RJ; Furman WL
    J Clin Oncol; 2007 Oct; 25(30):4806-12. PubMed ID: 17947729
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Everolimus for the treatment of advanced renal cell carcinoma.
    Amato R
    Expert Opin Pharmacother; 2011 May; 12(7):1143-55. PubMed ID: 21470068
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The mammalian target of rapamycin inhibitor everolimus (RAD001) in early breast cancer: results of a pre-operative study.
    Macaskill EJ; Bartlett JM; Sabine VS; Faratian D; Renshaw L; White S; Campbell FM; Young O; Williams L; Thomas JS; Barber MD; Dixon JM
    Breast Cancer Res Treat; 2011 Aug; 128(3):725-34. PubMed ID: 20941539
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Everolimus: targeted therapy on the horizon for the treatment of breast cancer.
    Barnett CM
    Pharmacotherapy; 2012 Apr; 32(4):383-96. PubMed ID: 22461124
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The mammalian target of the rapamycin (mTOR) kinase pathway: its role in tumourigenesis and targeted antitumour therapy.
    Janus A; Robak T; Smolewski P
    Cell Mol Biol Lett; 2005; 10(3):479-98. PubMed ID: 16217558
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Everolimus (RAD001): an mTOR inhibitor for the treatment of metastatic renal cell carcinoma.
    Oudard S; Medioni J; Aylllon J; Barrascourt E; Elaidi RT; Balcaceres J; Scotte F
    Expert Rev Anticancer Ther; 2009 Jun; 9(6):705-17. PubMed ID: 19496707
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting mTOR for cancer treatment.
    Rubio-Viqueira B; Hidalgo M
    Curr Opin Investig Drugs; 2006 Jun; 7(6):501-12. PubMed ID: 16784020
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.